[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-365685-105":59,"doc-detail-365685-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","immunoprevention-of-non-viral-cancers-challenges-and-strategies-for-early-intervention","Immunoprevention of non-viral cancers - challenges and strategies for early intervention","","Cancer vaccines have been studied extensively in treatment, but prevention and interception remain less explored. Non-viral cancers are harder to immunoprevent because late-stage tumors often respond poorly, influenced by an immunosuppressive microenvironment. This review emphasizes shifting intervention to early development and progression, targeting high-risk cohorts with defined molecular markers. It highlights evolving immune mechanisms, summarizes emerging preclinical evidence, and reviews preclinical and clinical strategies including neoantigen discovery, optimized immunomodulating agents, and vaccine optimization.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/immunoprevention-of-non-viral-cancers-challenges-and-strategies-for-early-intervention/365685/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/immunoprevention-of-non-viral-cancers-challenges-and-strategies-for-early-intervention/365685.png","ImageObject",300,407,{"name":92,"@type":93},"Alex Sinclair","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-20","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is immunoprevention for non-viral cancers challenging compared with viral-mediated cancers?","Question",{"text":112,"@type":113},"Because preventing non-viral cancers via immunopreventive vaccines is difficult, and late-stage tumors often show reduced responsiveness due to an immunosuppressive tumor microenvironment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What strategy does the review propose to improve vaccine efficacy?",{"text":117,"@type":113},"Intervene earlier in cancer development and progression, and focus on high-risk cohorts with defined molecular targets to enhance the effectiveness of immunopreventive approaches.",{"name":119,"@type":110,"acceptedAnswer":120},"Which research areas are highlighted for advancing cancer immunoprevention?",{"text":121,"@type":113},"The review discusses neoantigen discovery, the use and optimization of immunomodulating agents alone or with vaccines, and strategies for optimizing vaccines to improve immune control of tumor onset and progression.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},365685,1791254290,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099523882182,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Biswas et al. Cancer Cell International (2025) 25:196  \n[https://doi.org/10.1186/s12935-025-03817-8](https://doi.org/10.1186/s12935-025-03817-8)  \nCancer Cell International  \n REVIEW Open Access  \nImmunoprevention of non-viral cancers:  \nchallenges and strategies for early intervention  \nKajal Biswas 1, Lillian S. Kuo2, Robert H. Shoemaker 1,3* and Altaf Mohammed1,4*  \nAbstract  \nWhile the effects of cancer vaccines have been extensively studied in the therapeutic setting, research has been more limited in the areas of cancer prevention and interception. Although cancer prevention by vaccines has been possible for viral-mediated cancers, such as cervical cancers and hepatocellular carcinoma, preventing non-viral cancers by immunopreventive vaccines is challenging. Many tumors at late stages are less responsive to treatments, including immunotherapies and vaccines, in part due to an immunosuppressive microenvironment. Shifting the strategy to intervention at early stages of cancer development and progression and focusing on high-risk cohorts with defined molecular targets offers a pathway for improved vaccine efficacy. Current research on the role of immune mechanisms during tumor initiation and progression is rapidly evolving and recent emerging preclinical immunoprevention studies have shown that vaccines can induce host immune response and effectively control tumor onset and progression. In this review, we address important considerations and challenges regarding the development of cancer immunoprevention for non-viral cancers. We also discuss significant, innovative, and impactful preclinical and clinical immunoprevention studies in various cancers. This includes neoantigen discovery, the use and optimization of immunomodulating agents either alone or in combination with vaccines, and strategies for optimizing vaccines. We conclude by discussing prospects for immunoprevention research and potential opportunities to advance the field in the future.  \nKeywords Immunoprevention, Cancer prevention, Neoantigens, Cancer vaccine, Cancer interception  \n*Correspondence:  \nRobert H. Shoemaker [robert.shoemaker@nih.gov](robert.shoemaker@nih.gov)[ ](robert.shoemaker@nih.gov)Altaf Mohammed [altaf.mohammed@nih.gov](altaf.mohammed@nih.gov)  \n1 Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, MD, USA  \n2 Cancer Immunology, Hematology and Etiology Branch, Division of Cancer Biology, National Cancer Institute, Rockville, MD, USA  \n3 Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, 9609 Medical Center Drive, Room no: 4E454, Rockville, MD 20850, USA  \n4 Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, 9609 Medical Center Drive, Room no: 5E602, Rockville, MD 20850, USA  \nIntroduction  \nCancer initiation and progression is dependent on genetic and environmental risk factors and they are tightly interconnected with the immune system [1]. In general, preventing the development of cancer involves taking action to lower the risk of developing cancerous cells that can be achieved by avoiding exposure to known cancer-causing substances, maintaining healthy lifestyles, and using prophylactic vaccines. These riskreducing measures are considered primary prevention as they aim to prevent the initiation or development of malignancy. Along with avoidance of cancer risk factors, cancer prevention strategies also include active interventions that lead to the diagnosis and control of precancerous lesions at the earliest stage possible (Fig. 1). Cancer interception refers to disruption of the oncogenic process  \nThis is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distri","cbCaieZ1frxZRyzr","https://ap.wps.com/l/cbCaieZ1frxZRyzr","pdf",2850602,17,"English","# Abstract\n# Introduction\n## Cancer prevention vs interception\n## Immunoprevention vs immunotherapy","[{\"question\":\"Why is immunoprevention for non-viral cancers challenging compared with viral-mediated cancers?\",\"answer\":\"Because preventing non-viral cancers via immunopreventive vaccines is difficult, and late-stage tumors often show reduced responsiveness due to an immunosuppressive tumor microenvironment.\"},{\"question\":\"What strategy does the review propose to improve vaccine efficacy?\",\"answer\":\"Intervene earlier in cancer development and progression, and focus on high-risk cohorts with defined molecular targets to enhance the effectiveness of immunopreventive approaches.\"},{\"question\":\"Which research areas are highlighted for advancing cancer immunoprevention?\",\"answer\":\"The review discusses neoantigen discovery, the use and optimization of immunomodulating agents alone or with vaccines, and strategies for optimizing vaccines to improve immune control of tumor onset and progression.\"}]","Immunoprevention of non-viral cancers - challenges and strategies for early intervention | PDF",1790161815,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/66df1857c7d63bd9d17fd52d53d40453.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f53265126d076435a131c3c1c0867d86.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7b4e2872cab2ab4d9e53146d9a617bb2.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5f524edab1ad818636aba6457a090a3f.webp",980,1301]